Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Zenas BioPharma, Inc.
| Metric | Zenas BioPharma, Inc. ZBIOHealthcare |
|---|---|
| Quality Score | 62 / 100 |
| Revenue (latest) | $10M |
| Net income (latest) | −$378M |
| Operating margin | −3830.6% |
| Net margin | −3777.4% |
| Return on equity | −156.0% |
| Return on assets | −98.5% |
| Return on capital (ROCE) | −119.3% |
| Debt / equity | 0.58× |
| Revenue growth (YoY) | 100.0% |
| Altman Z″ (distress) | -6.48 |
| Accruals / assets | −53.5% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.